Table 2 Growth-inhibition efficacy data on ovarian cancer cell lines and normal cell lines treated with DAP compounds compiled from individual MTT assay
From: Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs
Cell lines | Cisplatin 10 μg/ml (%) | Curcumin 100 μM (%) | DAP-F (p) 10 μM (%) | DAP-F(p)-NOH 10 μM (%) | DAP-CF3(P) 10 μM (%) | DAP-CF3(P)-NOH 10 μM (%) |
|---|---|---|---|---|---|---|
A2780 | 75-85 | 65-75 | 80-90 | 75-85 | 80-90 | 80-90 |
A2780R* | 50-60 | 55-65 | 85-90 | 70-80 | 75-85 | 70-80 |
SKOV3 | 80-90 | 65-75 | 80-90 | 75-85 | 85-90 | 75-80 |
OVCAR3 | 70-80 | 65-70 | 75-80 | 80-85 | 75-85 | 70-80 |
OV-4 | 75-80 | 60-65 | 75-80 | 70-80 | 80-85 | 80-85 |
PA-1 | 65-75 | 50 | 65-75 | 70-75 | 75-80 | 75-80 |
hOSE | ☹ | ☺ | ☹ | ☺ | ☹ | ☺ |
CHO | ☹ | ☺ | ☹ | ☺ | ☹ | ☺ |
H9C2 | ☹ | ☺ | ☹ | ☺ | ☹ | ☺ |
HSMC | ☹ | ☺ | ☹ | ☺ | ☹ | ☺ |